Chemotherapy-Free Triplet ‘Sets a New Benchmark’ in Follicular Lymphoma

By News Health
1 hour Ago

(MedPage Today) — ORLANDO — Adding the bispecific antibody epcoritamab (Epkinly) to a standard chemotherapy-free regimen for relapsed or refractory follicular lymphoma improved responses and reduced the risk of disease progression or death…

Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118878

Author :

Publish date : 2025-12-07 21:18:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Sickle Cell Pain Management in the ED Remains Suboptimal

'This Would Be a Hugely Important Finding': What We Heard This Week

Alzheimer's Benefits May Continue After Donanemab Treatment Ends, Data Suggest

Hematocrit, Phlebotomy Benefits Seen With Rusfertide in PV

Potential Game-Changing Impact on Mismatched Unrelated Blood Cell Transplantation

TBI-Free Conditioning Before Transplant Effective in MRD-Negative B-ALL